BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NA-931 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NA-931\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06732245-250@assetmemo.bio
DTSTAMP:20261121T005839Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:NA-931: Phase 2 readout est. (NCT06732245)
DESCRIPTION:NA-931\, phase 2\, Obesity.\nStudy: Safety and Efficacy of NA-9
 31 and Tirzepatide in Adults Who Are Overweight or Obese\nEstimated primar
 y completion: 15 August 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/na-931#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06732245
URL:https://assetmemo.bio/drug/na-931#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
